Debt-free Balance SheetHaving no debt materially reduces fixed obligations and financial distress risk, giving management flexibility to fund operations via equity, partnerships, or grant funding. This durable balance-sheet strength supports continued R&D and commercialization efforts over the next several months.

Platform-focused Business ModelA clear platform offering—functional drug response testing for precision oncology—creates multiple durable revenue vectors: per-test clinical fees, pharma collaborations, and licensing. Structural demand for personalized oncology diagnostics supports recurring, contractable revenue potential over time.

Improving Cash Burn TrendMaterial narrowing of losses and reduced cash burn in 2024 indicates improving operating discipline or commercialization traction. A sustained improvement trend lowers near-term refinancing pressure and increases the chance of reaching breakeven within a multi-quarter horizon if continued.

Bears Say

Near-zero RevenueVolatile and effectively negligible revenue (declines to near-zero) signals weak commercial traction and makes scaling the test platform uncertain. Without sustainable test volumes or contracted revenue, the business struggles to convert R&D into durable, predictable income.

Negative Cash GenerationPersistent negative operating and free cash flow necessitate external funding to sustain R&D and commercialization. Over the medium term this creates dilution or financing risk, constrains reinvestment in sales/clinical adoption, and limits strategic flexibility if markets tighten.

Shrinking Equity And AssetsErosion of the capital base reduces the company’s financial cushion and ability to absorb setbacks. Even with no debt, a shrinking equity/asset base heightens solvency risk and increases the likelihood of needing dilutive funding or strategic partnerships to preserve operations.

2CUREX FAQ

What was 2cureX AB’s price range in the past 12 months?

2cureX AB lowest stock price was kr0.33 and its highest was kr5.52 in the past 12 months.

What is 2cureX AB’s market cap?

2cureX AB’s market cap is kr33.01M.

When is 2cureX AB’s upcoming earnings report date?

2cureX AB’s upcoming earnings report date is May 28, 2026 which is in 73 days.

How were 2cureX AB’s earnings last quarter?

2cureX AB released its earnings results on Feb 26, 2026. The company reported -kr0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.026.

Is 2cureX AB overvalued?

According to Wall Street analysts 2cureX AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does 2cureX AB pay dividends?

2cureX AB pays a Notavailable dividend of kr0.084 which represents an annual dividend yield of 11.26%. See more information on 2cureX AB dividends here

What is 2cureX AB’s EPS estimate?

2cureX AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 2cureX AB have?

2cureX AB has 25,102,917 shares outstanding.

What happened to 2cureX AB’s price movement after its last earnings report?

2cureX AB reported an EPS of -kr0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.15%.

Which hedge fund is a major shareholder of 2cureX AB?

Currently, no hedge funds are holding shares in SE:2CUREX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

2cureX AB

2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.